News
Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly improved” as compared to placebo—the second positive readout for the asset this week.
FEATURED STORIES
While the pathogen appears unlikely to trigger a pandemic, analysts see potential for Moderna to build goodwill amid a period of political pressure on vaccine manufacturers.
Clinical trial setbacks have limited the near-term opportunities for some of Daiichi Sankyo’s ADCs but the drug developer is betting near-term readouts will catapult it into the top tier of oncology companies in the coming years.
BioSpace analyzed the pay ratio across 10 major pharmaceutical companies to determine which CEOs were paid the most relative to typical employees. J&J, Eli Lilly and Pfizer once again topped the list.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
The Department of Health and Human Services is spinning its wheels, unable to establish steady leadership at three major divisions—the CDC and the FDA’s two primary review units.
THE LATEST
FDA Action Alert for February 7
Specialty vaccine company Valneva and Pfizer have reported positive Phase II data from their clinical trial evaluating a Lyme Disease vaccine candidate.
It was a relatively quiet week for clinical trial announcements. Here’s a look.
StrideBio, Exicure and Syndax Pharmaceuticals tapped new CEOs.
Novartis reported its full-year financials this week for 2021, and overall, the news was good. Of concern, however, is the company’s Sandoz generics unit.
On Thursday, Unity Biotechnology announced that it is cutting 50% of its workforce, mainly in the research department.
This particular renewal panel discussion took an unexpected turn, focusing on Biogen’s controversial drug.
UCB hit the mark in its Phase III clinical trial assessing zilucoplan, while Vanda failed its late-stage study of tradipitant.
Preclinical models indicate that pairing specific cancer treatments with precision nutritional interventions increased treatment efficacy by as much as 500%.
Data from Phase III ECHELON-1 clinical study conducted with either stage III or stage IV cHL showed consistent improvement in OS across each of the six 28-day cycles completed.